Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Another Phase III Study Supports Avastin Expansion To Ovarian Cancer

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Roche/Genentech's Avastin took another step toward an indication in ovarian cancer with the July 2 release of positive top-line results from a second Phase III study showing a benefit in progression-free survival

You may also be interested in...



NICE Rejects Roche’s Avastin In Advanced Ovarian Cancer

The U.K.'s health care cost regulator says it wouldn't recommend Roche's Avastin as a first-line treatment for advanced ovarian cancer along with standard chemotherapy, on grounds it doesn’t offer value for money.

Roche's Long View: ASCO Marks Progress In Shifting To Lengthier Treatment Duration For Avastin, Rituxan

CHICAGO - Roche's current focus in oncology is on establishing longer treatment durations for its oncologics, including its mega-blockbuster Avastin (bevacizumab)

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

Topics

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel